Suppr超能文献

产科实践中缩宫剂的风险效益评估。

A risk-benefit assessment of oxytocics in obstetric practice.

作者信息

Winkler M, Rath W

机构信息

Department for Obstetrics and Gynecology, University Hospital, Technical University, Aachen, Germany.

出版信息

Drug Saf. 1999 Apr;20(4):323-45. doi: 10.2165/00002018-199920040-00003.

Abstract

Substances that stimulate contractions of the myometrium have found wide applications in present day obstetrics. Above all, fully synthetic, uterus-selective prostaglandin analogues are used for preoperative priming of the cervix for termination of pregnancies in the first trimester as well as for the induction of abortions in the second trimester and have proved to have a much higher efficacy than oxytocin. Because of the pharmacological synergism of their cervix ripening and myometrium stimulating activities, the local use of natural prostaglandin E2 preparations (used intracervically as a gel or vaginally as a gel or as a tablet) is unequivocally superior to use of oxytocin with its almost exclusive contraction stimulating activity for induction of labour, especially for women with an unripe cervix. In women with a ripe cervix, oxytocin and prostaglandins are equally effective with oxytocin having the major advantage of its better controllability on continuous intravenous infusion (plasma elimination half-life of 10 minutes). Over the past 50 years, the use of oxytocin and ergot alkaloids preparations as prophylaxis against postpartum atonia has led to a marked reduction in maternal deaths. The same is true to a major extent for therapy for uterine atonia where the intravenous infusion of dinoprost is an indispensable and life-saving procedure after the failure of systemic administration of oxytocin or ergot alkaloid preparations. On the other hand, the administration of oxytocics can be accompanied by a wide range of adverse systemic and uterine effects and complications ranging from severe cardiovascular incidents with a fatal outcome through to the threat of uterine hyperstimulation with fetal asphyxia to uterine rupture. For these reasons, an adequate knowledge of the pharmacokinetics as well as the systemic and uterine activities and adverse effects of these substances is an essential prerequisite for every physician in evaluating differential indications for their use and adequate monitoring for mother and infant. Of particular importance is the use of prostaglandins for cervical priming prior to termination of pregnancies in the first and second trimesters and the use of native prostaglandin and oxytocin for inducing delivery in cases of fetal deaths as well as vital infants. Both substances play a decisive role at the beginning of delivery. Cervical priming and induction of contractions would not be conceivable without prostaglandin and oxytocin. The pharmacological properties of the 2 substances can be used in different ways for the induction of delivery. Oxytocin ergot alkaloids and prostaglandin are essential for the management of postpartum uterine atonia where their use often represents a decisive, life-saving intervention.

摘要

刺激子宫肌层收缩的物质在当今产科中有着广泛应用。首先,全合成的、子宫选择性前列腺素类似物被用于妊娠早期终止妊娠时宫颈的术前预处理,以及中期引产,并且已证明其疗效远高于缩宫素。由于其宫颈成熟和刺激子宫肌层活动的药理协同作用,局部使用天然前列腺素E2制剂(宫颈内使用凝胶剂,或经阴道使用凝胶剂或片剂)在引产方面明显优于几乎仅具有刺激收缩活性的缩宫素,尤其对于宫颈未成熟的女性。对于宫颈成熟的女性,缩宫素和前列腺素同样有效,缩宫素的主要优势在于持续静脉输注时更好的可控性(血浆消除半衰期为10分钟)。在过去50年中,使用缩宫素和麦角生物碱制剂预防产后宫缩乏力已使孕产妇死亡显著减少。在治疗宫缩乏力方面情况同样如此,在缩宫素或麦角生物碱制剂全身给药失败后,静脉输注地诺前列素是必不可少的挽救生命的措施。另一方面,使用宫缩剂可能会伴随广泛的全身和子宫不良影响及并发症,从导致致命后果的严重心血管事件到子宫过度刺激威胁胎儿窒息甚至子宫破裂。出于这些原因,充分了解这些物质的药代动力学以及全身和子宫活性及不良反应,是每位医生评估其使用的不同适应证并对母婴进行充分监测的必要前提。特别重要的是,在妊娠早期和中期终止妊娠前使用前列腺素进行宫颈预处理,以及在胎儿死亡及存活婴儿的情况下使用天然前列腺素和缩宫素引产。这两种物质在分娩开始时都起着决定性作用。没有前列腺素和缩宫素,宫颈预处理和宫缩诱导将无法想象。这两种物质的药理特性可用于不同方式引产。缩宫素、麦角生物碱和前列腺素对于产后宫缩乏力的处理至关重要,其使用往往是决定性的、挽救生命的干预措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验